PrintContact
 
  • Home
  • About Us
  • Sativex
  • R&D
  • Investors
  • Media
GW Pharmaceuticals

Meeting patients' needs...

Our vision

...is to be the global leader in prescription cannabinoid medicines, through the rapid cost-effective development of pharmaceutical products which address clear unmet patient needs.

 
PATIENTS

Therapeutic areas of focus, clinical trials and other information on Sativex...

Click here

 
MEDICAL PROFESSIONALS

Prescriber information, clinical publications and other information on Sativex...

Click here

 
MEDIA

Press releases, frequently asked questions and contact information for media enquiries...

Click here

 
INVESTORS

Share price, regulatory news, company presentations and other investor information..

Click here

 
 

Latest News

31 August 2010

Health Canada Grants Full Approval of Sativex For the Treatment of Spasticity Due to Multiple Sclerosis

28 July 2010

Sativex® receives regulatory authorisation in Spain

News archive

Sportlight

sativex

Sativex® UK approval

More Info

Click here for more info regarding this medicine

 

SHARE PRICE

GBp 103.00

0.75p 03/09/201016:49 BST

 
 
 

© GW Pharmaceuticals 2009

  • Home
  • Sitemap
  • Accessibility
  • Disclosure & Disclaimer
  • Contact
  • Email Alerts
 

Website designed and developed by www.emperordesign.co.uk